Skip to main content
padlock icon - secure page this page is secure

Open Access Progress in global rollout of new multidrug-resistant tuberculosis treatments

Download Article:
 Download
(PDF 248.9 kb)
 
SETTING: The global multidrug-resistant tuberculosis (MDR-TB) epidemic has grown over the past decade and continues to be difficult to manage. In response, new drugs and treatment regimens have been recommended.

OBJECTIVE: In 2017 and again in 2018, the International Union Against Tuberculosis and Lung Disease (The Union) drug-resistant (DR) TB Working Group collaborated with RESIST-TB to implement an internet survey to members of The Union around the world to assess access to these new treatment strategies.

DESIGN: A nine-question survey was developed using SurveyMonkey®. The survey was open for participation to all members of The Union registered under the TB Section. Two reminders were sent during each survey. The responses were analyzed taking into account the WHO Region to which the respondent belonged.

RESULTS: The 2018 survey showed a global increase in implementation of the shorter (9-month) MDR-TB regimen (from 33% to 56% of respondents, P < 0.001) and an increase in the use of bedaquiline and/or delamanid (from 25% to 41% of respondents, P < 0.001) compared to 2017. There were substantial variations in roll-out between WHO regions.

CONCLUSION: These results demonstrate improvement in global implementation of the new treatment strategies over a 1-year period.
No Reference information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: TB; bedaquiline; delamanid; drug-resistant tuberculosis

Document Type: Research Article

Affiliations: 1: Department of Global Health, Boston University School of Public Health, Boston, MA 2: Partners In Health, Boston, MA, USA 3: Department of Tuberculosis and HIV, International Union Against Tuberculosis and Lung Disease (The Union), Paris, France, Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 4: Department of Tuberculosis and HIV, International Union Against Tuberculosis and Lung Disease (The Union), Paris, France 5: Departments of Epidemiology, Biostatistics and Global Health, Boston University School of Public Health, and Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, USA

Publication date: September 1, 2019

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more